Status:
UNKNOWN
Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer
Lead Sponsor:
Laibin People's Hospital
Conditions:
Lung Cancer Stage III
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
Study Object: Stage III lung cancer with epidermal growth factor receptor (EGFR) sensitive mutation. Study Method: The study subjects will be randomly assigned to the intervention group and the contr...
Detailed Description
The following tasks need to be completed at the time of enrollment: screening, signing the informed consent form, random assignment according to the randomization table, detailed patient medical histo...
Eligibility Criteria
Inclusion
- Patients initially diagnosed with lung cancer through imaging and pathological examination.
- Genetic testing confirms EGFR-sensitive mutations.
- Staging according to the international eighth edition of lung cancer TNM is between stage ⅢA to ⅢC.
- Age between 18 to 80 years old, without severe organ diseases such as heart, liver, kidney, etc.
- ⑤ General condition assessed with a performance status (PS) score of ≤2 points.
Exclusion
- ① Patients with upper gastrointestinal physiological disorders, malabsorption syndrome, intolerance to oral medications, or peptic ulcers.
- Patients who have received previous radiotherapy or chemotherapy for lung conditions.
- Patients with concomitant chronic obstructive pulmonary disease, atelectasis, or other conditions that cause difficulties in lesion measurements.
- Patients with active pulmonary tuberculosis. ⑤ Patients with respiratory failure. ⑥ Patients with allergies to the investigational drugs used in this study. ⑦ Pregnant or lactating women. ⑧ Patients with any other diseases, neurological or metabolic disorders, physical examination or laboratory findings that may raise reasonable suspicions of certain diseases or conditions, which would either disqualify the use of the investigational drugs or place the subjects at high risk of treatment-related complications.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 8 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05994339
Start Date
September 1 2023
End Date
December 8 2025
Last Update
August 29 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.